M. J. Mulligan

Inflammation durably imprints memory CD4+ T cells

This study compares transcriptional and epigenetic differences in Spike-specific CD4+ T cell memory between individuals primed by SARS-CoV-2 infection versus mRNA vaccination.

Increased resistance of SARS-CoV-2 Omicron Variant to Neutralization by Vaccine-Elicited and Therapeutic Antibodies

The paper assesses Omicron's resistance to vaccine and monoclonal antibody neutralization, finding boosters improve efficacy but existing therapies are largely ineffective.

Neutralization of Mu and C.1.2 SARS-CoV-2 Variants by Vaccine-elicited Antibodies in Individuals With and Without Previous History of Infection

This study evaluates neutralization of SARS-CoV-2 Mu and C.1.2 variants by vaccine-elicited and convalescent antibodies, finding that vaccine-induced responses remain protective despite partial resistance.

Two-dimensional multiplexed assay for rapid and deep SARS-CoV-2 serology profiling and for machine learning prediction of neutralization capacity

This paper introduces a 2D-MBBA assay for SARS-CoV-2 serology profiling and uses machine learning to predict neutralization capacity from antibody profiles.

Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants

This study compares neutralizing antibody titers from mRNA and adenoviral vector vaccines against SARS-CoV-2 variants, finding lower neutralization against variants for Ad26.COV2.S and suggesting a second dose may improve protection.

SARS-CoV-2 Lambda Variant Remains Susceptible to Neutralization by mRNA Vaccine-elicited Antibodies and Convalescent Serum

This study assesses the neutralization efficacy of convalescent sera and mRNA vaccine-elicited antibodies against the SARS-CoV-2 lambda variant, finding minimal reduction in neutralizing titers.

The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies.

This study evaluates the neutralization resistance of SARS-CoV-2 B.1.617 and B.1.618 spike proteins to vaccine-elicited and therapeutic antibodies, finding partial resistance due to specific mutations.

Optimized Quantification of Intrahost Viral Diversity in SARS-CoV-2 and Influenza Virus Sequence Data

This study evaluates variant calling tools for detecting minority variants in viral sequencing data and provides guidance for accurate quantification of intrahost viral diversity.

B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies

The paper assesses neutralization of B.1.526 SARS-CoV-2 variants by vaccine-elicited and therapeutic antibodies, finding minimal impact on neutralizing titers.

Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies

This study evaluates the neutralizing activity of convalescent sera and BNT162b2 vaccine antibodies against SARS-CoV-2 variants, showing reduced efficacy against B.1.351 due to E484K mutation but overall maintained protection.

High titers of multiple antibody isotypes against the SARS-CoV-2 spike receptor-binding domain and nucleoprotein associate with better neutralization.

The paper assesses neutralization capacity and antibody titers against SARS-CoV-2 antigens in recovered healthcare workers, finding that high titers of multiple isotypes correlate with neutralization.